title: [Anxiolytic afobazole action self-evaluated by patients with anxiety-asthenic disorders].
abstract: Self-evaluation of single-dose (15 mg) action and course treatment (30 mg daily) results were studied in patients with anxiety and asthenic disorders treated with the new anxiolytic afobazole. Also, relationships between self-evaluated parameters and personal features, clinician-rated therapeutic changes, and treatment effectiveness were analyzed. The study was conducted according to formalized protocol using standard scales and methods. Results suggest that higher self-rated tolerability and patient acceptability were associated with afobazole treatment in comparison to benzodiazepines. The results revealed relationships between self-evaluated single-dose effects of afobazole and other parameters, personal features, cognitive impairments severity, main drug effects, and overall treatment effectiveness.
authors.forename: M A
authors.initials: MA
authors.lastname: Reutova
authors.forename: S A
authors.initials: SA
authors.lastname: Siuniakov
authors.forename: T S
authors.initials: TS
authors.lastname: Siuniakov
authors.forename: G G
authors.initials: GG
authors.lastname: Neznamov
mesh_terms: D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy* / Q000523:psychology; D001247:Asthenia / Q000188:drug therapy* / Q000523:psychology; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000209:etiology / Q000523:psychology; D059026:Diagnostic Self Evaluation; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D010349:Patient Compliance; D017060:Patient Satisfaction; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D014151:Anti-Anxiety Agents; D001562:Benzimidazoles; D009025:Morpholines